Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference. Read more about Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference.
Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model. Read more about Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model.
Neoadjuvant sipuleucel-T induces both Th1 activation and immune regulation in localized prostate cancer. Read more about Neoadjuvant sipuleucel-T induces both Th1 activation and immune regulation in localized prostate cancer.
Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models. Read more about Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models.
Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy. Read more about Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy.
Shuffling the deck with CTLA-4 therapy: Deep sequencing of rearranged TCRB genes demonstrates T cell repertoire remodeling in cancer patients. Read more about Shuffling the deck with CTLA-4 therapy: Deep sequencing of rearranged TCRB genes demonstrates T cell repertoire remodeling in cancer patients.
Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma. Read more about Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma.
Age, estrogen, and immune response in breast adenocarcinoma and adjacent normal tissue. Read more about Age, estrogen, and immune response in breast adenocarcinoma and adjacent normal tissue.
Prioritization schema for immunotherapy clinical trials in glioblastoma. Read more about Prioritization schema for immunotherapy clinical trials in glioblastoma.
GM-CSF and ipilimumab therapy in metastatic melanoma: Clinical outcomes and immunologic responses. Read more about GM-CSF and ipilimumab therapy in metastatic melanoma: Clinical outcomes and immunologic responses.
